🔗 Permalink

Inventor profile of:

Thomas Weimer

City:

Gladenbach

Country:

Germany

Published Applications:

Last publication date:

2022-11-03

Top Assignees for applications by Thomas Weimer

The entities that hold a legal rights for patent applications filed by inventor Weimer Thomas:

CSL BEHRING GMBH 18 Marburg, Germany
CSL Behring Lengnau AG 7 Lengnau, Switzerland
Novozymes Biopharma UK Limited 2 Nottingham, United Kingdom
NOVOZYMES BIOPHARMA DK A/S 1 Bagsvaerd, Denmark
Novozymes Delta Limited 1 Nottingham, United Kingdom
Aventis Behring GmbH 1 Marburg, Germany
DYAX CORP. 1 Cambridge, MA United States
CSL BEHRING LENGNAU AG 1 Lengnau BE, Switzerland
CSL Ltd. 1 Parkville, Australia
Delta Biotechnology Limited 1 Nottingham, United Kingdom
CSL Innovation Pty Ltd 1 Melbourne, Australia

Recent patent applications by Weimer Thomas

Thomas Weimer from Gladenbach, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-11-03

US20220348637A1

Chemistry; metallurgy

POLYPEPTIDES FOR INDUCING TOLERANCE TO FACTOR VIII

#2 | 2022-05-19

US20220154161A1

Chemistry; metallurgy

FACTOR IX VARIANTS AND USES THEREOF IN THERAPY

#3 | 2021-09-02

US20210268071A1

Human necessities

Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

#4 | 2021-04-29

US20210121535A1

Human necessities

Methods for preparing modified von Willebrand Factor

#5 | 2020-11-26

US20200368327A1

Human necessities

Methods for preparing modified von Willebrand factor

#6 | 2020-06-25

US20200197495A1

Human necessities

Modulation of FVIII immunogenicity by truncated VWF

#7 | 2020-03-26

US20200095567A1

Chemistry; metallurgy

PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY

#8 | 2019-08-29

US20190263890A1

Chemistry; metallurgy

Truncated von Willebrand Factor polypeptides for treating hemophilia

#9 | 2018-06-14

US20180161402A1

Human necessities

Truncated von Willebrand factor polypeptides for treating hemophilia

#10 | 2018-06-07

US20180153968A1

Human necessities

Methods for preparing modified von Willebrand factor

#11 | 2018-05-03

US20180119128A1

Chemistry; metallurgy

PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY

#12 | 2018-04-05

US20180092966A1

Human necessities

COVALENT COMPLEX OF VON WILLEBRAND FACTOR AND FACTOR VIII, COMPOSITIONS, AND USES RELATING THERETO

#13 | 2018-02-22

US20180051067A1

Chemistry; metallurgy

Modified von Willebrand factor having improved half-life

#14 | 2017-03-23

US20170080061A1

Human necessities

MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE

#15 | 2016-07-14

US20160200794A1

Chemistry; metallurgy

Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto

#16 | 2016-01-14

US20160010074A1

Chemistry; metallurgy

PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY

#17 | 2014-12-04

US20140357564A1

Chemistry; metallurgy

Von willebrand factor variants having improved factor VIII binding affinity

#18 | 2014-12-04

US20140356346A1

Chemistry; metallurgy

MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE

#19 | 2014-09-18

US20140273096A1

Chemistry; metallurgy

MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE

#20 | 2014-09-04

US20140248686A1

Chemistry; metallurgy

THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY

#21 | 2014-03-13

US20140072561A1

Chemistry; metallurgy

Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life

#22 | 2013-12-19

US20130337532A1

Chemistry; metallurgy

THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY

#23 | 2012-10-11

US20120258072A1

Human necessities

Interleukin-11 Fusion Proteins

#24 | 2011-08-04

US20110189182A1

Chemistry; metallurgy

PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY

#25 | 2011-07-28

US20110183907A1

Chemistry; metallurgy

Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life

#26 | 2011-05-26

US20110124565A1

Chemistry; metallurgy

Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives

#27 | 2011-04-21

US20110092413A1

Chemistry; metallurgy

Albumin-Fused Kunitz Domain Peptides

#28 | 2010-11-04

US20100279923A1

Chemistry; metallurgy

Therapeutic application of Kazal-type serine protease inhibitors

#29 | 2010-09-02

US20100222554A1

Chemistry; metallurgy

Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides

#30 | 2010-06-10

US20100143973A1

Human necessities

Interleukin-11 Fusion Proteins

#31 | 2010-05-13

US20100120664A1

Chemistry; metallurgy

Modified coagulation factors with prolonged in vivo half-life

#32 | 2009-12-03

US20090298760A1

Human necessities

Modified coagulation factor VIIa with extended half-life

#33 | 2009-09-10

US20090227775A1

Chemistry; metallurgy

HIV Inhibiting Proteins

#34 | 2009-07-09

US20090175828A1

Chemistry; metallurgy

Coagulation factor X polypeptides with modified activation properties

#35 | 2009-06-25

US20090162871A1

Chemistry; metallurgy

Mutants of the factor VII-activating protease and detection methods using specific antibodies

#36 | 2009-05-21

US20090130060A1

Chemistry; metallurgy

Modified vitamin K dependent polypeptides

#37 | 2009-02-26

US20090053185A1

Chemistry; metallurgy

Coagulation factor X polypeptides with modified activation properties

#38 | 2009-02-12

US20090042787A1

Chemistry; metallurgy

Proteolytically cleavable fusion proteins with high molar specific activity

#39 | 2008-11-27

US20080293638A1

Chemistry; metallurgy

ALBUMIN-FUSED CILIARY NEUROTROPHIC FACTOR

#40 | 2008-11-27

US20080292581A1

Human necessities

Interleukin-11 Fusion Proteins

#41 | 2008-11-06

US20080274969A1

Chemistry; metallurgy

Albumin-Fused Kunitz Domain Peptides

#42 | 2008-10-23

US20080260755A1

Chemistry; metallurgy

Proteolytically cleavable fusion proteins with high molar specific activity

#43 | 2007-05-03

US20070099229A1

Chemistry; metallurgy

Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations

#44 | 2006-12-26

US10391215

Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis

#45 | 2006-10-26

US20060241027A1

Chemistry; metallurgy

Hiv inhibiting proteins

#46 | 2006-08-10

US20060178301A1

Chemistry; metallurgy

Albumin-fused ciliary neurotrophic factor

#47 | 2005-10-06

US20050222023A1

Chemistry; metallurgy

Albumin-fused kunitz domain peptides

#48 | 2005-02-10

US20050032109A1

Chemistry; metallurgy

Mutants of the factor VII-activating protease and detection methods using specific antibodies

InventorID:

577255 ⎘